Development and validation of a patient-reported gout attack intensity score for use in gout clinical studies

Rheumatology (Oxford). 2019 Nov 1;58(11):1928-1934. doi: 10.1093/rheumatology/kez064.

Abstract

Objective: Inflammation-related symptoms such as pain, swelling and tenderness of the affected joint are frequently assessed using 5-point diary rating scales in gout clinical trials. Combining these into a single gout attack symptom intensity score may be a useful summary measure for these data, which is potentially more responsive to change compared with the individual components. The objective of this study was to develop a patient-reported gout flare intensity score, the Gout Attack Intensity Score (GAIS), for use in clinical studies, that includes components for gout-related pain, swelling and tenderness.

Methods: Data from a randomized controlled trial comparing anakinra to standard of care for the treatment of acute gout attacks were used for this study. A 7-day flare diary was completed by patients, including questions relating to intensity of pain, swelling and tenderness (5-point rating scales). Scalability of these items was assessed using Mokken Scale Analysis, and reliability using greatest lower bound reliability coefficients. Known-groups validity was evaluated, as well as the responsiveness to change and the presence of floor and ceiling effects.

Results: Scalability of the single items was supported, and GAIS scores were reliable (greatest lower bound >0.80). GAIS scores demonstrated responsiveness to change with high effect sizes (>0.8), and discriminated better between responders and non-responders compared with its single-item components. No floor and ceiling effects were found.

Conclusion: The GAIS seems to be a reliable and responsive instrument for assessing patient-reported gout attack intensity that may be used in gout clinical studies.

Keywords: gout attack intensity; outcome measure; pain; swelling; tenderness.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antirheumatic Agents / therapeutic use
  • Colchicine / therapeutic use
  • Double-Blind Method
  • Female
  • Gout / drug therapy
  • Gout / pathology*
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Male
  • Middle Aged
  • Patient Reported Outcome Measures*
  • Randomized Controlled Trials as Topic
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Severity of Illness Index*
  • Symptom Assessment / methods
  • Symptom Assessment / standards*
  • Symptom Flare Up*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein
  • Colchicine